This activity will assist learners in identifying optimal lifestyle and behavioral changes that can impact disease development and progression in their patients and will discuss practical strategies and forms of support that HCPs can offer to assist patients in setting healthy lifestyle goals. Learners will examine how appropriate prescribing decisions must be based on a comparative analysis of diabetes medications and will also review disease etiology and biological changes seen during disease progression. Lastly, the presenter will discuss policy and system changes that can best assist in integrating evidence into daily practice for the purpose of maximizing health in individuals with T2D. 

This activity will present HCPs with the information necessary to evaluate kidney health in individuals with type 2 diabetes mellitus (T2DM) and will discuss CKD risk stratification, including interpretation of albuminuria levels and estimated glomerular filtration rate (eGFR). Interventions that can reduce progression of disease, likelihood of hospitalization and costs will be identified, and recent data about effective treatment regimens and their indications for improving outcomes will be examined. Additionally, early strategies to decrease the risk for CVD and ESRD in these individuals will be defined, with a review of the pathophysiology of progression of these disorders. 

This activity will provide an overview on direct-to-consumer (DTC) genetic testing, the role of HCPs in helping consumers make educated decisions about using these services and the future of DTC genetic testing.

This activity will review the rationale, mechanisms of action, and indications for current FDA-approved anti-obesity pharmacotherapies, as well as explore medications that have weight-loss-promoting potential.